Associated tags: Woman, Endometriosis, FDA, Gynaecology, Ovarian cancer, Aspira, Conference
Locations: NEW YORK, UNITED STATES, MASSACHUSETTS, CHICAGO, ILLINOIS, FLORIDA, CANADA, KENYA, AUSTIN, TX, TEXAS, CALIFORNIA
Retrieved on:
Thursday, November 9, 2023
AUSTIN, Texas, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced that during the 2024 Clinical Laboratory Fee Schedule (CLFS) rate setting process, the Centers for Medicare & Medicaid Services (CMS) has proposed to crosswalk the fee paid to the company for OvaWatch to the fee paid historically for Ova1. If finalized later this month (as was preliminarily approved in September), Aspira would be reimbursed at a rate of $897 for all OvaWatch and Ova1 tests processed for Medicare patients meeting applicable coverage requirements beginning in January 2024. The public comment period ended on October 27.
Key Points:
- If finalized later this month (as was preliminarily approved in September), Aspira would be reimbursed at a rate of $897 for all OvaWatch and Ova1 tests processed for Medicare patients meeting applicable coverage requirements beginning in January 2024.
- “Crosswalking” refers to a process for setting the Medicare reimbursement rate for a new laboratory test by assigning the new code the same rate as a comparable existing test.
- Aspira supports the proposal to crosswalk OvaWatch to Ova1 and believes it is appropriate given the similarity of pre-analytical, analytical, and post-analytical characteristics of the two assays.
- “We are one step closer to achieving our mission of ensuring this ground-breaking technology is available to all women when they are facing an ovarian cancer diagnosis.”
Retrieved on:
Tuesday, October 31, 2023
AUSTIN, Texas, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced that the company will report its financial results for the three months ended September 30, 2023 on Monday, November 13, 2023.
Key Points:
- AUSTIN, Texas, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced that the company will report its financial results for the three months ended September 30, 2023 on Monday, November 13, 2023.
- Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30 p.m. Eastern Time.
- Details for the call are as follows:
Conference call & Webcast Details:
Retrieved on:
Wednesday, October 25, 2023
Ovarian cancer,
Research,
Gynaecology,
Harvard Medical School,
Dana–Farber Cancer Institute,
AACR,
Assistant,
MicroRNA,
Conference,
Protein,
Poster,
Reproductive biology,
Serum,
Aspira,
Patient,
Cancer,
Metadata,
Hospital,
Medical imaging,
Obstetrics,
Brigham AUSTIN, Texas, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases today announced that a poster on an in-development miRNA-based ovarian cancer test was presented at the AACR Special Conference in Cancer Research: Ovarian Cancer, held on October 5, 2023 in Boston, MA.
Key Points:
- AUSTIN, Texas, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases today announced that a poster on an in-development miRNA-based ovarian cancer test was presented at the AACR Special Conference in Cancer Research: Ovarian Cancer, held on October 5, 2023 in Boston, MA.
- The poster, entitled: “Improving the diagnostic accuracy of an ovarian cancer triage test using a joint miRNA-protein model,” highlighted data showing miRNA’s potential to improve the diagnostic accuracy of non-invasive diagnostic tests.
- The study combined serum protein and patient clinical information (metadata) from Aspria’s ovarian cancer registry studies with miRNA determined by the Elias laboratory.
- The analysis shows the potential for improving ovarian cancer diagnostics by combining our trusted technology with miRNA.
The Clinical Advisory Board will provide clinical input and guidance throughout the development of the Company’s portfolio of products.
Key Points:
- The Clinical Advisory Board will provide clinical input and guidance throughout the development of the Company’s portfolio of products.
- Each member of the board is a recognized thought-leader with deep clinical expertise in gynecologic health.
- “With the creation of the Clinical Advisory Board, we are able to maximize the impact of expert clinicians who believe in the potential of our technology.
- He has served on the ASCCP Board and joined the Executive Committee in 2019 and is the current ASCCP President.
Retrieved on:
Friday, September 29, 2023
AUSTIN, Texas, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced that Nicole Sandford, Chief Executive Officer, will present a brief corporate overview at the BioVenture Nexus Conference at 4:30 pm PDT on October 5, 2023.
Key Points:
- AUSTIN, Texas, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced that Nicole Sandford, Chief Executive Officer, will present a brief corporate overview at the BioVenture Nexus Conference at 4:30 pm PDT on October 5, 2023.
- The conference is taking place at the JW Marriott – The Ritz Carlton DTLA on October 5-6, 2023, in Los Angeles, CA.
- To register for the conference, click HERE.
Retrieved on:
Wednesday, September 13, 2023
AUSTIN, Texas, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced that it received written notice from the Nasdaq Stock Market LLC (“NASDAQ”) on September 12, 2023 informing the Company that it has regained compliance with the market value of listed securities (“MVLS”) requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) (the “Rule”) for continued listing on the Nasdaq Capital Market.
Key Points:
- AUSTIN, Texas, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced that it received written notice from the Nasdaq Stock Market LLC (“NASDAQ”) on September 12, 2023 informing the Company that it has regained compliance with the market value of listed securities (“MVLS”) requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) (the “Rule”) for continued listing on the Nasdaq Capital Market.
Retrieved on:
Monday, September 11, 2023
Department of Medical Microbiology (Schering AG),
Abstract,
Pelvic inflammatory disease,
Bachelor of Science,
University,
Apotex,
Medical microbiology,
HIV,
Cangene,
HIV-1,
Head,
Monoclonal antibody,
Public Health Agency of Canada,
COVID-19,
Woman,
CIHR,
Infection,
Research,
Lehigh University,
American Biological Safety Association,
National Microbiology Laboratory,
University of Manitoba,
Government,
Immunochemistry,
Chlamydia trachomatis,
Philosophy,
Outline,
Gynaecology,
Blood,
Scripps Research,
Protein engineering,
R,
Public Health Agency,
G.H. Raisoni Department of Microbiology and Biotechnology,
University Arena (Western Michigan University),
Vaccine,
Science,
Chlamydia,
Molecular biology,
Aspira AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced it has named Jody Berry, Ph.D. as its new Chief Scientific Officer.
Key Points:
- AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced it has named Jody Berry, Ph.D. as its new Chief Scientific Officer.
- Dr. Berry is a seasoned scientific leader with over two decades of commercial, government and academic experience.
- Jody is a dynamic leader with decades of experience launching disruptive products and building effective research and development teams,” said Nicole Sandford, Chief Executive Officer of Aspira.
- Dr. Berry is author or co-author on over 100 peer-reviewed published journal articles, abstracts, scientific posters, and monographs.
Retrieved on:
Thursday, August 31, 2023
Endometriosis,
University,
University of Oxford,
Woman,
Nuffield Department of Population Health,
Pain,
Patient,
Algorithm,
Diagnosis,
Chronic pain,
Medical device,
Aspira AUSTIN, Texas, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical based diagnostic company focused on gynecologic health, today announced a material transfer agreement with The University of Oxford for the procurement of serum samples to be used to verify and validate the Company’s endometriosis blood test algorithms. Aspira expects to use the samples to support the launch of EndoCheckSM, its first-generation blood test to aid in the diagnosis of endometriosis, by the end of 2023.
Key Points:
- AUSTIN, Texas, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical based diagnostic company focused on gynecologic health, today announced a material transfer agreement with The University of Oxford for the procurement of serum samples to be used to verify and validate the Company’s endometriosis blood test algorithms.
- Aspira expects to use the samples to support the launch of EndoCheckSM, its first-generation blood test to aid in the diagnosis of endometriosis, by the end of 2023.
- “We are excited to enter into this agreement with The University of Oxford.
- We are excited to support Aspira Women’s Health in developing a much-needed test for the identification of this debilitating disease.”
AUSTIN, Texas, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development of women’s health diagnostic tools for gynecologic diseases, today announced that Nicole Sandford, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference, which is scheduled to take place on September 11-13, 2023 in New York, NY.
Key Points:
- AUSTIN, Texas, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development of women’s health diagnostic tools for gynecologic diseases, today announced that Nicole Sandford, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference, which is scheduled to take place on September 11-13, 2023 in New York, NY.
- Management will also be available for one-on-one meetings.
- Details are as follows:
The webcast will also be available for viewing and replay on the Investor Relations portion of the Company’s website.
AUSTIN, Texas, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc.(“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development of women’s health diagnostic tools for gynecologic diseases, today announced it has named Michelle Snider as Senior Vice President, Commercial Strategy and Operations.
Key Points:
- AUSTIN, Texas, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc.(“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development of women’s health diagnostic tools for gynecologic diseases, today announced it has named Michelle Snider as Senior Vice President, Commercial Strategy and Operations.
- She joins Aspira from Sema4 Genomics where she served as Vice President of Market Enablement/Sales Strategy during the company’s extraordinary growth.
- In this role, she was responsible for women’s health commercial strategy and oversaw its financial and operational performance.
- “Michelle has experience successfully launching new products as well as accelerating commercial growth for more mature offerings.
